up to date!The seventh batch of national collection results first look at: the maximum decrease of 97%, the influenza magic medicine is 1 yuan/piece; foreign companies continue to "lie down".

Today (July 12), in Nanjing, the seventh batch of drug countries, which turned around for nearly half a year, finally settled down, bid farewell to the sixth batch of insulin special episodes, and the competition returned to the field of chemical and injections.

In this collection, a total of 61 varieties, 125 rules, according to Mine.com data, the terminal market size is nearly 70 billion yuan. Nearly 300 eligible pharmaceutical companies participated in the competition of today's bidding places.

I have to say that the "confidentiality" work of this collection is very good. Compared with the lively from 11 am, the news that flowed out in the afternoon was still very small.

▲ The quotation site, from: network

According to the latest official release, this collection has a successful procurement (or a variety of bids), and the average price reduction of drugs is 48%(lower than before). According to the agreed purchase volume, it is expected to save 18.5 billion yuan each year. Yuan.

According to the current news:

Omeprazole injection, originally researching Astrikon, 40mg, limited to 14 yuan

Harbinlian quoted at 0.69 yuan, a price limit of 95%compared to the price limit, and won the first place in the most competitive varieties.

North China Pharmaceuticals, Hang Seng Pharmaceuticals, and Fuan Pharmaceutical Hubei People's Pharmaceuticals were priced at 0.8 yuan, and a decrease of about 94%, all of which were slightly higher than Harbin Sanlian and entered the top four of Omeprazole.

The Coron Pharmaceutical Newspaper is 0.92 yuan, the Bosen Biological News is 1.03 yuan, and Hainan Quanxing Pharmaceutical is priced at 1.09 yuan; all of which will win the bid with a decrease of over 90%.

The front -line of liver cancer targeted Yaolilunkinib, 4mg, limited to 108 yuan

Xianyou Pharmaceutical won the bid at a minimum price of 3.6 yuan, a decrease of 97%, becoming the king of price reductions.

Oshwe Weitou takes a long -term release type, originally developed Robe, 75mg, limited to 13.01 yuan

East Sunshine quoted 1.13 yuan, a decrease of 91.3%, winning the bid at the lowest price at the lowest price;

Qilu Pharmaceutical offer 2.77 yuan, a decrease of 78.7%, and successfully won the bid for the bidding

Roche quoted 20.06 yuan, exceeding the limit of 7 yuan, "lying flat and abandoning the bid"

Meiro Peinan injection, the original study of Japanese residents, 0.25g, limited to 18.70 yuan

Luo Xin's pharmaceutical offer is 8.01 yuan, a decrease of 57%, or the first place win the bid for the first place

Hanhui Pharmaceutical offer 8.82 yuan

The quotation of stone medicine European Yiyi is 11.87 yuan, which is the highest price currently collected.

Edala's injection, 20ml: 30mg, limited to 25 yuan, the original research on Mitsubishi, Tianbian, Japan

Jilin Bo University 3.79 yuan, a decrease of 84.8%, the first place winning the bid;

Harbin Triangle 4.8 yuan, a decrease of 80.8%, or winning the second place in the second place

Qilu and Yangtze River were quoted by 6 yuan, respectively, and the bid was won accordingly.

Cefchomypes are overpowered, 100mg, limited to 1.48 yuan

Qilu quoted 0.33 yuan, a decrease of 78%, or the first

Shandong Haishan offer 0.35 yuan, or second

Chengdu Beite is almost the same, reported at 0.38 yuan

Baiyun Mountain, Guangdong has not dropped, and reported to 1.48 yuan, which is deemed to have given up.

Yili for Kang Kangju, the original Research Pfizer, 2ml: 40mg, limited to 295 yuan, which belongs to the highest unit price of the audience

Hainan Jinrui was 29.8 yuan, a decrease of 90%, or the first place won the bid for the first place.

Hengrui 46.2 yuan, a decrease of 84%, should be bidding

Qilu 56 yuan, a decrease of 81%, should be bidding

Sulfuric acid special solution, 2ml: 5mg: 5mg, limit of 3.398 yuan

Hebei Renheyi Kang was quoted at 0.957 yuan, a decrease of 71.8%, and the first place won the bid.

The health yuan was 1.128 yuan, a decrease of 66.8%, and the second place won the bid.

Hengdao Medicine was 1.15 yuan, a decrease of 66.1%, which was 0.02 yuan from health yuan and the third place.

Hongsen Pharmaceutical and Prett Pharmaceuticals were priced at about 1.3 yuan respectively, winning the bid.

Shijiazhuang Four Medicine 1.39 yuan, eliminated according to the 7 -in -5 rules.

Astraikon's 4.293 price limit, exceeding the price of nearly 1 yuan, "lying flat and abandoning the bid."

Lotflotmine, 10mg, limit of 2.486 yuan;

Mero Pharmaceutical was 0.41 yuan, a decrease of 83.5%, or the first place won the bid;

Qilu Pharmaceutical offer 0.52 yuan, a decrease of 84%

Hebei Wanliu Pharmaceutical offer is 0.55 yuan

Like Mero, the "last bus" won the bid (July 7th Rating) and Li Pin Pharmaceutical 0.67 yuan, a decrease of 73%

Avotptide injection, the original research Nuohua, 1ml: 0.1mg, a limit price of 22.64 yuan, the bidding is almost the same, basically around 16 yuan, of which:

The first biochemical quotation of the medicine is the lowest, 15.98 yuan, a decrease of 29%, and the bid rules of the "1.8 times, 50%, 1 cup" are not reached.

Note: The above -mentioned declines are compared with the price limit, and everything is subject to official release data. Most of the data below are artificial statistics, or they are not comprehensive, for reference only.

The most intense variety of competition in the audience, Omeprazole declined by 95%

In this collection, it has been officially posted in February. Because of the epidemic and other reasons, it officially started in July. The 5 months extended this round of competing and the gangsters. , Resulting in competition more intense.

Among them, Omela defeated 28 finalists to compete on the same stage. According to the shortlisted rules of up to 10, the elimination rate exceeded 60%, which is the most intense variety in this game.

*Omeprazole injection is mainly used to treat gastric ulcers, duodenal ulcers, etc. It is also called "gastric disease and god medicine". It is the most commonly used proton pump inhibitor in clinical practice. , Stable in sales first. At present, only the quotation information of 10 companies is collected for this variety, or because many companies are "scared" by competition conditions.

Prior to the collection, according to the Chinese market data in 2020, Ogon, Astraikon, and Lingkang in Hainan ranked among the top three with 41.55%, 14.31%, and 6.5%of the Omeprazole market share.

However, in this collection, the three companies have not flowed out of the offer. If they give up, it is equivalent to "arming" the original advantage market.

At present, Omeprazole injection, originally Research Astraikon, 40mg, limited to 14 yuan

Harbin Lianlian quoted 0.694 yuan, a decrease of 95%, becoming the king of price reductions, and the first place in the most competitive varieties won the bid.

North China Pharmaceuticals, Hang Seng Pharmaceuticals, and Fuan Pharmaceutical Hubei People's Pharmaceuticals were priced at 0.8 yuan, and a decrease of about 94%, all of which were slightly higher than Harbin Sanlian and entered the top four of Omeprazole.

The Coron Pharmaceutical Newspaper is 0.92 yuan, the Bosen Biological News is 1.026 yuan, and Hainan's full -star pharmaceutical offer is 1.09 yuan; all of which will win the bid with more than 90%.

It is reported that the figure of proton pump inhibitors first appeared in the third batch of episodes for the first time, and there have been seven varieties that have been included so far. It is foreseeable that in the next 1-2 years, the market size of proton pump inhibitors will usher in a sharp decline.

"Influential medicine" is no longer glorious, the price drops to 1 yuan/piece

Olympic Wei, as a "influenza magic medicine", benefited from the East Sunshine Pharmaceutical. According to Mine.com, in 2019, in China, a total of 6.5 billion yuan in Chinese public medical institutions and Chinese urban physical pharmacies, Oasiswell's total sales exceeded 6.5 billion yuan East Sunshine medicine occupies 90 %, and sales are close to 6 billion yuan. The remaining 10%of the market share was occupied by the original medicine Luo Shi.

However, while everyone pays attention to the safe distance and the social epidemic of the mask, the influenza magic medicine also loses the use of martial arts.

East Sunshine Financial Report,

In 2020, Olyvawei's sales totaled about 2.068 billion yuan (accounting for 88.1%of revenue), a significant decrease of 65.1%from 2019.

In 2021, Oasiswell's sales revenue was 554 million yuan, a year -on -year decrease of more than 73%.

In this collection, Oasis Veye takes a dosage form, 75mg, limited to 13.01 yuan

East Sunshine quoted 1.13 yuan, a decrease of 91.3%, winning the bid at the lowest price at the lowest price. Although the market share is gradually minimizing, it is still strongly replaced;

Qilu Pharmaceutical offer 2.77 yuan, a decrease of 78.7%, and successfully won the bid for the bidding

Roche quotes 20.06 yuan, exceeding the limit of 7 yuan, giving up the advantage market

Another large variety, Yili Daidekang injection, has a market size of about 1.5 billion. It is a special effect of Japan's first pharmaceutical development and launching and treating advanced colorectal cancer in 1994. It is now a product of Pfizer.

According to Mine.com data, in 2018, the sales of Yili Kangju in China Public Medical Institutions terminals were 1.662 billion yuan, of which Hengrui accounted for an absolute advantage, with a market share of over 60%. The current pattern is 1+5. Good opportunity.

In addition, it is worth noting that in this collection, Ilide Kangju is the highest unit price of the audience.

At present, Yili Detkang injection, 2ml: 40mg, limited to 295 yuan,

Hainan Jinrui was 29.8 yuan, a decrease of 90%, or the first place won the bid, and the barefoot counterattack

Hengrui is 46.2 yuan, a decrease of 84%, retaining some advantages;

Qilu 56 yuan, a decrease of 81%, should be bidding

Foreign companies are still "lying flat" and they are not interested in participation

In this collection, there are not a few varieties in foreign companies.

Pfizer led with 5 varieties.

4 varieties of Novartis.

Roche, Merck, and Astraon are respectively three varieties.

Among the first five batches of pharmaceuticals, Pfizer and Asleykang each have a variety of bids. Novartis and Roche have no variety to win the bid. Foreign companies still adopt the same "retreat" strategy.

For example, in the auction of solution in inhalation of the sulfuric acid atomization inhalation, 2ml: 5mg, the price limit is 3.398 yuan

Astraikon quoted 4.293 yuan, exceeding the limit of nearly 1 yuan, and directly "lying down the bid".

Osdifer Vehicle takes a long -term release formation, 75mg, limited to 13.01 yuan

Roche quoted 20.06 yuan, exceeding the limit of 7 yuan, and also "lying flat and abandoning the bid"

It is worth noting that the three varieties selected this time are Omeprazole injections, Metololol, and Tibci Lynch. The market share of dosage forms and Tabchen has exceeded 90%, and it will definitely affect after the bid.

The quotation data of other foreign companies has not yet flowed out, or the quotation of this collection is not involved in the collection.

Self -funded Yidala, the "barefoot" enterprise got the top spot

In this collection, the most special product of the audience is Edala, and there are two special labels on it: key monitoring medicines+self -funded medicine.

Edala Feng is a brain protective agent (free radical clearance agent), which is used to improve the neurological symptoms, daily life activity and dysfunction caused by acute cerebral infarction, and inhibit functional disorders caused by muscle atrophy. Progress.

Edala Feng is a well -known large variety, TOP4 variety of terminal neuromances of Chinese public medical institutions. According to Mine.com data, in 2019, the domestic sales of this drug reached 5.2 billion yuan.

In the competitive landscape, Edala was first developed by the Mitsubishi Pharmaceutical Co., Ltd. in Japan. In the domestic market, Edala is the first domestic pharmaceutical company in China. In 2019, the sales of the pioneering Pharmaceutical Edra (required) in the injection (required) reached 940 million yuan. About 20%of the product sales revenue of the pharmaceutical company during the same period, the proper head of Huadan.

According to the current news, according to the current news, the quotation of Xianyin Pharmaceutical is 80 yuan, far exceeding the limited price of 25 yuan, which is the highest quotation currently collected, or the price of the product cannot be accepted, and it is expressed by the attitude of "abandonment".

In fact, before this round of collection, Edala's sales have grown weakly. In 2019, the drug was included in the "First Batch of National Key Monitoring Reasonable Drug Catalogs", excluded from medical insurance, sales growth began to slow, and even began to grow negatively in 2018.

For example, the must -store of pilot pharmaceuticals,

In 2018, sales reached 1.1986 billion yuan,

In 2019, after entering the key monitoring, sales suddenly dropped to 936.9 billion yuan.

In the first half of 2020, the revenue was -68.92%year-on-year, only 178 million yuan.

In this collection, some "barefoot" companies have counterattacked. According to the current news, Edala's injection, 20ml: 30mg, limited to 25 yuan

Jilin Bo University 3.79 yuan, a decrease of 84.8%, the first place winning the bid;

Harbin Triangle 4.8 yuan, a decrease of 80.8%, or winning the second place in the second place

Qilu and Yangtze River were quoted by 6 yuan, respectively, and the bid was won accordingly.

Such a high decline will inevitably get a market share under medical insurance commitment. However, for the "must -survivors", the days in the future may be more difficult.

The "last bus" reported 0.4 yuan/piece; Housen Pharmaceutical 5 consecutive China

On the last day of the collection of collection, more than a dozen companies stepped on the bureau, such as Conicap capsules in Zhejiang Asia Pacific; Line Fluotic Pot Fluotic Pot in Lipin Pharmaceutical (Xiamen) and Mero Pharmaceuticals; Amber of Yichang Renfu Amber Sour Metolol's slow -release tablets, etc., were obtained in China on July 7th to get effective domestic registration approval and set foot in the seventh batch of last bus.

According to the current news, in the bidding group with 10mg and a price limit of 2.486 yuan, the latecomer Pharmaceutical Pharmaceutical and Mero have won the bid to become the winner of the "last bus", of which:

Mero Pharmaceutical was 0.41 yuan, a decrease of 83.5%, or the first place won the bid;

Li Pin Pharmaceutical was 0.67 yuan, a decrease of 73%.

In addition, the current news, Haosen Pharmaceutical performed well this time, and the five models were included in the product bid, including the injection of Mikafen's net sodium, Malayic acid analidininib, hydrochloride tablets, and apple acid sannyinyiniic sour sosamic sour picotin, and apple acid souriniic acid sulfini. Tenini, Lula Siraidone tablets.

According to the previous news, in the 3-5 batch of collection, Haosen has a good record of winning the bid. The third batch of 4 parades, 4 bits and 4 paragraphs, and the fifth batch of 5 varieties also all won the bid.

Attachment: The seventh batch of collection of bidding data is currently out of the bidding data, Fengyun medicine talks and sort out

· END ·

- END -